Stock ANPATH GROUP, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases Anpath Group, Inc. OTC Bulletin Board

Equities

US03634J1060

End-of-day quote OTC Bulletin Board
Other stock markets
- USD - Intraday chart for Anpath Group, Inc.
03/05 Telix Pharmaceuticals (Us) Inc. completed the acquisition of QSAM Biosciences, Inc. from Checkmate Capital Group LLC, Strategic Planning Assets Limited and others. CI
20/03 QSAM Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
QSAM ANNOUNCES REVERSE STOCK SPLIT RATIO AHEAD OF MERGER
AQ
QSAM Biosciences Signs Definitive Agreement to be Acquired by Telix Pharmaceuticals
AQ
QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals; Receives $2 Million Pre-Closing Collaboration and Option Fee
AQ
QSAM Biosciences Provides Update to Shareholders on Phase 1 Progress and Preliminary Clinical Data
AQ
QSAM BIOSCIENCES, INC. : Unregistered Sale of Equity Securities (form 8-K)
AQ
QSAM Biosciences Adds the Nuclear Reactor at the University of Texas at Austin to its Radioisotope Production Supply Chain for its Bone Cancer Treatment Drug Candidate, CycloSam®
AQ
QSAM Biosciences Expands its Study of CycloSam® in the Treatment of Bone Cancer; Opens Patient Enrollment at Key Chicago Center, Insight Hospital and Medical Center
AQ
QSAM Biosciences and RLS Announce Clinical and Commercial Supply Agreement for Promising Clinical-Stage Metastatic and Primary Bone Cancer Treatment, CycloSam®
AQ
QSAM Biosciences Receives Second Key Patent in Europe for its Clinical Stage Radiopharmaceutical Drug Candidate, CycloSam®
AQ
QSAM BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
QSAM Biosciences Opens Enrollment of the Second Cohort of Patients in its Phase 1 Study of CycloSam Targeting Metastatic Bone Cancer
AQ
QSAM Biosciences Opens Enrollment of the Second Cohort of Patients in its Phase 1 Study of CycloSam® Targeting Metastatic Bone Cancer
AQ
QSAM BIOSCIENCES, INC. : Unregistered Sale of Equity Securities (form 8-K)
AQ
QSAM BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
QSAM Biosciences to Provide Updates on its Clinical Trial at the Emerging Growth Conference on Wednesday, March 22, 2023
AQ
QSAM Biosciences Receives Clearance from FDA to Expand Enrollment Criteria in its Phase 1 Study of CycloSam® Targeting Metastatic Bone Cancer
AQ
QSAM Biosciences Completes Enrollment of Initial Cohort in its Phase 1 Study of CycloSam® Targeting Metastatic Bone Cancer
AQ
QSAM Biosciences Recruits the Ellis Fischel Cancer Center at the University of Missouri as Clinical Trial Site to Further Expand and Advance the Study of CycloSam® for Bone Cancer
AQ
QSAM BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
QSAM Biosciences to Present at the Emerging Growth Conference on Wednesday, January 25, 2023
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. QSAM Stock
  4. Stock
  5. News Anpath Group, Inc.
  6. Press Releases